Fulgent Genetics, Inc.: directors' dealings · United States · SEC (Form 4)

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a U.S.-based diagnostics and laboratory technology company listed on NASDAQ under the ticker FLGT, in the United States. For European investors, the company fits squarely in the healthcare and pharma ecosystem: it focuses on clinical genomics, molecular testing, anatomic pathology, and a smaller therapeutic development business. Founded in 2011, Fulgent built its franchise around two guiding ideas highlighted by management from the outset: flexibility and affordability. The company’s headquarters are in El Monte, California, where it also maintains a major portion of its laboratory and administrative footprint. Fulgent’s core business is its laboratory services segment. That segment includes precision diagnostics, anatomic pathology, and biopharma services. Its test portfolio spans rare disease, hereditary cancer, reproductive health, and a broad set of oncology applications. Technologically, the company uses next-generation sequencing (NGS), cytogenetics, fluorescence in situ hybridization (FISH), immunohistochemistry, molecular genetics, flow cytometry, and specialist pathology interpretation. This broad panel offering is important strategically: it allows Fulgent to compete not only as a test vendor, but as a multi-technology platform capable of supporting complex clinical decision-making. Operationally, the group runs multiple CLIA-certified laboratories across the United States, including sites in California, Texas, Massachusetts, Arizona, and Georgia. That footprint gives it national reach in the U.S. market and supports a diversified referral base. The company also serves some international demand, although its revenue remains overwhelmingly U.S.-driven. In its 2024 segment disclosure, Fulgent reported that the bulk of revenue came from the United States, with smaller contributions from China and other foreign markets. From a competitive standpoint, Fulgent operates in a crowded and highly regulated market alongside large reference laboratories and specialized molecular diagnostics players. Its relative differentiation comes from the breadth of its test menu, its ability to develop and commercialize complex assays, and its combination of laboratory services with software-enabled workflows. The company has also been expanding through targeted acquisitions in anatomic pathology, strengthening its position in a service area that complements molecular testing. In March 2026, it completed the acquisition of Bako Diagnostics and StrataDx, adding pathology capability, proprietary PCR tests, and a broader national client base. Recent corporate milestones also matter for the investment case. In July 2025, Fulgent received EU CE marking for FulgentExome and FulgentPLM, an important regulatory validation for its germline sequencing platform. In February 2025, Foundation Medicine announced a partnership with Fulgent to launch hereditary germline tests in the United States. Taken together, these developments suggest a company that is trying to deepen its role in precision diagnostics, broaden its technical platform, and create incremental growth opportunities beyond its legacy testing base.